Alexander Menter

Learn More
BACKGROUND Efalizumab, a T-cell-targeted, recombinant, humanized, monoclonal IgG1 antibody, inhibits key T-cell-mediated steps in the pathogenesis of psoriasis. Efalizumab is approved for the treatment of moderate-to-severe chronic plaque psoriasis in adults in more than 50 countries. OBJECTIVES To evaluate the efficacy and safety of long-term, continuous(More)
BACKGROUND Psoriasis is associated with several comorbidities and behavioural risk factors. OBJECTIVES To evaluate demographic and disease characteristics in patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). METHODS PSOLAR is a global, prospective, longitudinal, disease-based registry that includes a postmarketing(More)
PURPOSE Exisulind (sulindac sulfone, FGN-1, Aptosyn) is a sulindac metabolite that induces apoptosis via inhibition of cyclic GMP-phosphodiesterase. This agent demonstrated tumor growth inhibition in rodent models of colon, breast, prostate, and lung carcinogenesis. In an orthotopic model of human non-small-cell lung cancer, the combination of exisulind and(More)
Tofacitinib (CP-690,550) is a novel, oral Janus kinase inhibi-tor that is currently being investigated as a targeted immuno-modulator for the treatment of several autoimmune diseases such as psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, and dry eye disease, and for prophylaxis of renal transplant(More)
BACKGROUND Drug survival is a marker for treatment sustainability in chronic diseases such as psoriasis. OBJECTIVE The aim of these analyses was to assess survival of biologic treatments in the PSOriasis Longitudinal Assessment and Registry (PSOLAR). METHODS PSOLAR is a large, prospective, international, disease-based registry of patients with psoriasis(More)
  • 1